Navigation Links
Study: mechanism that controls cell movement linked to tumors becoming more aggressive
Date:12/7/2010

Athens, Ga. Researchers at the University of Georgia have discovered a central switch that controls whether cells move or remain stationary. The misregulation of this switch may play a role in the increased movement of tumor cells and in the aggressiveness of tumors themselves.

"Malignant cancer arises when cancer cells acquire the ability to move away from their primary tissue location," said Natalia Starostina assistant research scientist in the UGA department of cellular biology and lead author of the research. "The control of cell movement is a fundamental aspect of animal development, and defects in cell movements can have devastating results ranging from tumor metastasis to vascular disease."

The movement of cells requires the "remodeling" of a supporting cell structure called the actin cytoskeleton. Starostina's research focused on how actin remodeling is controlled and how this regulates the movement of cancer cells.

The study was just published in the journal Developmental Cell. In addition to Starostina, other authors include Jennifer Simpliciano, undergraduate student; Michael McGuirk, lab technician; and Edward Kipreos, head of the lab. Cellular biology is a division of biological sciences in the Franklin College of Arts and Sciences.

The research by Kipreos' group focused on an unlikely source to control cell movement, a CKI protein.CKIs were originally identified as inhibitors of the cell cycle that function in the nucleus to prevent cells from dividing. Surprisingly, in the last few years, scientists noticed that certain very aggressive tumor cells had high levels of CKI in the cytoplasm, which is the part of the cell surrounding the nucleus.

Kipreos' team discovered that a protein known as LRR-1 degrades a CKI called p21 specifically in the cytoplasm of human cells. If LRR-1 is inactivated, then p21 accumulates in the cytoplasm, where it induces the remodeling of the actin cytoskeleton and increases cell movement. One unique aspect of this discovery is that LRR-1 only affects p21 levels in the cytoplasm (where p21 regulates the actin cytoskeleton) but not in the nucleus (where p21 inhibits cell division).

"The finding that LRR-1 controls p21 levels only in the cytoplasm was unexpected," said Kipreos, who also is a researcher in the UGA Cancer Center.

The accumulation of p21 in the cytoplasm causes the rearrangement of the actin cytoskeleton so that rod-like filaments made of actin are broken down, and the released actin is relocated to the periphery of cells where it promotes cell movement.

"While it was known that p21 is involved in remodeling the cytoskeleton, nobody had looked at its effects on cell motility," said Kipreos.

Scientists had previously observed that the accumulation of cytoplasmic p21 in a number of human cancers is associated with high tumor grade and poor prognosis. The Kipreos team's research shows that tumor cells with cytoplasmic CKI have increased movement, suggesting the reason these tumor cells are more aggressive is because their enhanced cell movements lead to metastasis in which the cancer spreads through the body.

"This work provides a key insight into how the movement of cells is controlled and explains why cancers with high cytoplasmic CKI levels are so aggressive," said Kipreos.

The team's initial breakthrough in linking LRR-1 to the degradation of CKI came from studying the small roundworm Caenorhabditis elegans. They found that in the worm LRR-1 specifically degrades the nuclear form of CKI to allow cells to divide.

"We thought it was very interesting that in worms, LRR-1 degrades a CKI in the nucleus to regulate cell division, while in humans, it degrades a CKI in the cytoplasm to control cell movement," said Starostina.

Exactly how the new information might be used to develop diagnostics or therapies to treat cancer awaits development. But the discovery of this new regulatory pathway gives researchers a target that could one day allow them to slow the spread of tumors or halt cancer cells in their tracks.


'/>"/>

Contact: Edward Kipreos
ekipreos@cb.uga.edu
706-542-3862
University of Georgia
Source:Eurekalert

Related biology news :

1. Illinois study: Ginseng just got better -- not as bitter
2. Study: Ecological effects of biodiversity loss underestimated
3. Study: Fish near coal-fired power plants have lower levels of mercury
4. National study: Abortion does not cause depression or low self-esteem in adolescents
5. VCU study: Team uncovers possible risk gene for schizophrenia
6. Study: 3 out of 4 cats will wear a collar, making it worth a try
7. Study: The bright red of cardinals means less in urban areas
8. Exploratory study: High BMI linked to proximity to convenience stores
9. Study: Darwin was right to worry that marriage to his cousin affected his offspring
10. Study: Carbon monoxide exposure can be reduced during routine anesthesia in kids
11. New study: The kitchen-counter diet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... 12, 2017   Protein Sciences Corporation , ... Flublok Influenza Vaccine ®, announced today that ... good safety results and induced strong neutralizing antibodies ... product is expected to advance into human clinical ... the Institute of Technology in Immunobiologicals of the ...
(Date:1/12/2017)... , ... January 12, 2017 ... ... rapid adoption of Limfinity® Cloud, RURO has enhanced the platform to accommodate ... groups, federated login, rapid data searching, and more. In addition to these ...
(Date:1/11/2017)... ... January 11, 2017 , ... As a ... Peru studying the pathogens that cause malaria and tuberculosis. Seeing firsthand the ravages ... discovery. , Now, as an assistant professor of biology and biotechnology at Worcester ...
(Date:1/11/2017)... Yorba Linda, Ca (PRWEB) , ... January 11, ... ... in the U.S. each year and costing healthcare systems more than $23.7 billion, ... patients while controlling costs. , Among the most common sepsis-causing pathogens are ...
Breaking Biology Technology: